Remove 2022 Remove Licensing Remove Trials
article thumbnail

Actithera draws new investors to radiopharma drug pitch

BioPharma Drive: Drug Pricing

Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from Dive Brief Actithera draws new investors to radiopharma drug pitch The four-year-old biotech raised about $75 million in a Series A round that involved nine venture capital firms.

article thumbnail

From siloed data to breakthroughs: multimodal AI in drug discovery

Drug Target Review

Clinical genomics, powered by NGS, enables more precise target validation, improved patient stratification and optimised trial design, ultimately aiming to increase PoS. Only in this way can AI reach its full potential in accelerating drug discovery and improving trial success rates. Highlighting data integration.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Inavolisib

New Drug Approvals

2022 Dec 22;65(24):16589-16621. Epub 2022 Dec 1. 19] Society and culture Legal status In October 2024, the US Food and Drug Administration (FDA) approved inavolisib for the treatment of PIK3CA -mutant breast cancer based on the results from the INAVO120 trial. [3] December 2022). J Med Chem. doi: 10.1021/acs.jmedchem.2c01422.

FDA
article thumbnail

Tofersen

New Drug Approvals

“Biogen’s antisense ALS drug shows promise in early clinical trial” FierceBiotech. January 2022). Tofersen , sold under the brand name Qalsody , is a medication used for the treatment of amyotrophic lateral sclerosis (ALS). [3] It is administered as an intrathecal injection. [3] 3 November 2006. January 2024.

article thumbnail

Elacestrant 

New Drug Approvals

Lloyd MR, Wander SA, Hamilton E, Razavi P, Bardia A (2022). Clinical trial number NCT03778931 for “Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer” at ClinicalTrials.gov ^ Jump up to: a b c Wardell SE, Nelson ER, Chao CA, Alley HM, McDonnell DP (October 2015).

FDA
article thumbnail

Vamorolone

New Drug Approvals

Hoffman, Efficacy and safety of vamorolone vs placebo and prednisone among boys with duchenne muscular dystrophy: a randomized clinical trial, JAMA Neurol. 79 (2022) 1005–1014. [71] 79 (2022)1005–1014 Bioorg. “Drug Trials Snapshots: Agamree” U.S. Shale, U.J. Reeves, E.P. Hoffman, K. Nagaraju, J.M. e201800186.

FDA
article thumbnail

Bayer Expands Collaboration with Tsinghua University to Boost Pharma R&D in China

The Pharma Data

One of the signature initiatives launched during the partnership was the Bayer Microfunding Program , introduced in 2022. Notably, over 80% of Bayer’s major global multi-center clinical trials now include study sites in China, spanning early-phase development to late-stage pivotal trials.